PCSK9 and its clinical importance with the new therapeutic targets against dyslipidemia
This is a remarkable progress; since the finding of statins, there was no new way of reducing, significantly, cholesterol and LDL fraction. It is also clear that this decrease, by statins, is related to future cardiovascular lesions, being useful in its primary and secondary prophylaxis. The authors presented studies on research to promote the falling of blood cholesterol by means of antibodies, which inhibit the pro-protein PCSK9, as well as agents that act performing the RNA interference. We had two advantages immediately: for patients with myopathy associated with statins, and the fact of being injected every 15 days, that may contribute to better treatment adherence.
Saved in:
Main Authors: | Ferreira,Carlos Eduardo dos Santos, Fonseca,Francisco Antônio Helfenstein, Mangueira,Cristóvão Luis Pitangueira |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Instituto Israelita de Ensino e Pesquisa Albert Einstein
2012
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082012000400024 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PCSK9 Inhibitors: Clinical Relevance, Molecular Mechanisms, and Safety in Clinical Practice
by: Ferrari,Filipe, et al.
Published: (2019) -
New cholesterol targets for patients at high or very high cardiovascular risk and the indications for PCSK9 inhibitors
by: Klug,E Q, et al.
Published: (2020) -
PCSK9 inhibitors in the current management of atherosclerosis
by: Whayne Jr,Thomas F.
Published: (2017) -
New Cholesterol Targets of SBC Guidelines on Dyslipidemia
by: Magalhães,Maria Eliane Campos
Published: (2017) -
Actualidad de los Inhibidores de la PCSK9
by: Lago Deibe,Fernando, et al.
Published: (2019)